Related Experiment Video

Updated: Jun 12, 2025

Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.4K

Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology

Jennifer Lloyd1, Nazy Zomorodian2, Geeta Devgan3

  • 1University of Utah.

Clinical Journal of Oncology Nursing
|September 26, 2024
PubMed
Abstract

Insights

Oncology nurses and APPs are vital for administering talazoparib plus enzalutamide to patients with HRR-deficient metastatic castration-resistant prostate cancer (mCRPC). They ensure safe dosing, administration, and management of adverse events for effective treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Approximately 25% of advanced prostate cancer patients exhibit homologous recombination repair (HRR) gene alterations.
  • Talazoparib plus enzalutamide demonstrated significant progression-free survival benefits in HRR-deficient metastatic castration-resistant prostate cancer (mCRPC) in a phase 3 trial.

Purpose of the Study:

  • To review the critical role of oncology nurses and advanced practice providers (APPs) in the administration of talazoparib plus enzalutamide.
  • To highlight the importance of nurses and APPs in managing adverse events associated with this treatment regimen.

Main Methods:

  • A review of current literature and a hypothetical case study were employed.
  • The methods focused on illustrating the practical application of administering talazoparib plus enzalutamide and managing potential side effects.

Main Results:

  • Oncology nurses and APPs are essential in the precise dosing and administration of talazoparib plus enzalutamide.
  • These healthcare professionals effectively identify and manage adverse events in patients with HRR-deficient mCRPC, ensuring treatment safety and efficacy.

Conclusions:

  • Oncology nurses and APPs are integral to the successful treatment of HRR-deficient mCRPC with talazoparib plus enzalutamide.
  • Their expertise in administration and adverse event management is crucial for optimal patient outcomes.
Keywords:
adverse eventsenzalutamidemCRPCtalazoparibtreatment management

More Related Videos

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant05:18

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

1.3K
Retzius-Sparing Robot-Assisted Radical Prostatectomy12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Nursing Ethical Principles II01:27

Nursing Ethical Principles II

Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
932
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
331